The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial

• Main Authors: Kerry-Ann F. O'Grady (Author), Anne B. Chang (Author), Allan Cripps (Author), Edward K. Mulholland (Author), Heidi Smith-Vaughan (Author), Nicholas Wood (Author), Margaret Danchin (Author), Ruth Thornton (Author), Andrew Wilson (Author), Paul J. Torzillo (Author), Peter M. Morris (Author), Peter Richmond (Author), Sheree Rablin (Author), Daniel Arnold (Author), Ann Connor (Author), Vikas Goyal (Author), Tanya Stoney (Author), Kirsten Perrett (Author), Keith Grimwood (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We aimed to determine the efficacy of the 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in children aged 18-months to <18-years with recurrent protracted bacterial bronchitis (rPBB), chronic suppurative lung disease (CSLD) or bronchiectasis. In a multi-centre...